Favrille Reports Fourth Quarter and Year End 2007 Financi... (portion of debt ...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> BIOLOGY >> TECHNOLOGY

Favrille Reports Fourth Quarter and Year End 2007 Financial Results

Date:2/19/2008

portion of debt 5,275 4,976

Warrants liability 2,492 -

Total current liabilities 11,318 11,755

Debt, less current portion 6,342 5,754

Deferred rent 15,415 10,145

Commitments and contingencies

Stockholders' equity:

Preferred stock, $0.001 par value 5,000,000

shares authorized; no shares issued

and outstanding at December 31, 2007 and 2006,

respectively - -

Common stock, $0.001 par value 75,000,000

shares authorized; 41,168,432 and 29,060,081

issued and outstanding at December 31, 2007

and 2006, respectively 41 29

Additional paid-in capital 233,807 200,497

Accumulated other comprehensive income 7 3

Deficit accumulated during the development

stage (198,975) (155,894)

Total stockholders' equity 34,880 44,635

Total liabilities and stockholders' equity $67,955 $72,289

FAVRILLE, INC.

(a development stage company)

STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

Three months ended

Years ended December 31, December 31,

2007 2006 2007 2006

(unaudited) (unaudited) (unaudited)

Operating expenses:

Research &

development $34,864 $31,050 $7,764 $7,680

<

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. Favrille Announces $21.1 Million Registered Direct Offering
2. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
3. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
4. Favrille to Present at BIO InvestorForum
5. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
6. Favrille CEO to Present at Bear Stearns Healthcare Conference
7. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
8. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
9. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
10. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
11. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer

Post Your Comments:

Breaking Biology Technology:Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 2 Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 3 AEterna Zentaris Announces Appointment of New Board Member 2 Waters Ships First Units of SYNAPT G2 Mass Spectrometer 2 Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 2 Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 3 Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 4

[0] Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease [0] AEterna Zentaris Announces Appointment of New Board Member [0] Waters Ships First Units of SYNAPT G2 Mass Spectrometer [0] Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009

Other Biology Technology:Bioheart, Inc. to Present at Red Chip Investor Conference in New York 2 The First Ever Transplantation World-Wide of Entire Arms at the "Klinikum rechts der Isar" in Munich 2 AMDL Updates Q2 and FY2008 Guidance 2 AMDL Updates Q2 and FY2008 Guidance 3

Bioheart, Inc. to Present at Red Chip Investor Conference in New York The First Ever Transplantation World-Wide of Entire Arms at the "Klinikum rechts der Isar" in Munich AMDL Updates Q2 and FY2008 Guidance

Breaking Biology News(10 mins):Canna can: Ornamental eliminates pollutants from stormwater runoff 2 Berkeley Lab researchers participate in Homeland Security study of subway airflow 2 Studies Highlight a Revolutionary New Method of Treating Post Operative Bruising 48245 1 Studies Highlight a Revolutionary New Method of Treating Post Operative Bruising 48245 2 Studies Highlight a Revolutionary New Method of Treating Post Operative Bruising 48245 3 Studies Highlight a Revolutionary New Method of Treating Post Operative Bruising 48245 4 Frost 26 Sullivan 3A Replacement of Old Equipment Boosts Kenyan Medical Imaging Industry 48242 1 Frost 26 Sullivan 3A Replacement of Old Equipment Boosts Kenyan Medical Imaging Industry 48242 2 Frost 26 Sullivan 3A Replacement of Old Equipment Boosts Kenyan Medical Imaging Industry 48242 3 Frost 26 Sullivan 3A Replacement of Old Equipment Boosts Kenyan Medical Imaging Industry 48242 4 Mayor Manny Diaz Commissioner Heyman Rep Brise Community Health Leaders and Healthcare Workers to Hold Press Conference to Push for Healthcare Ref 48240 1 Mayor Manny Diaz Commissioner Heyman Rep Brise Community Health Leaders and Healthcare Workers to Hold Press Conference to Push for Healthcare Ref 48240 2

[0] NASA news highlights at American Geophysical Union Meeting [0] Canna can: Ornamental eliminates pollutants from stormwater runoff [0] Berkeley Lab researchers participate in Homeland Security study of subway airflow

Other Biology News:Protein structure determined in living cells 2 Taking the pulse of our planet 2 Safeway gives $685,000 to TGen for breast cancer research 2

Protein structure determined in living cells Taking the pulse of our planet Safeway gives $685,000 to TGen for breast cancer research

Biology Products:

IMAGEQUANT 300 IQTL from GE Healthcare, formerly Amersham Biosciences Feline IL-12 / IL-23 p40, Unconjugated from R&D Systems HybriWell™ hybridization sealing system, 20 mm diameter chamber, 0.15 mm deep *set of 100* from Molecular Probes (Invitrogen)dithiothreitol (DTT) from Molecular Probes (Invitrogen)